FDA Action Awaits Lupin Sites As Compliance Cloud Lingers
Executive Summary
Lupin continues to face the heat for compliance deviations at its manufacturing plants, with the FDA now issuing an official action indicated inspection classification for two of the Indian company's sites. Lingering negative sentiment and remediation costs are some aspects that investors may need to brace for.
You may also be interested in...
Lupin Slapped With Fresh FDA Warning Letter
Lupin has announced that the US FDA has slapped its Mandideep plant in central India with a warning letter after the company failed to fix compliance problems detected by inspectors in late 2018.
Lupin Results Fail To Cheer But Signal Stabilization Of US Generic Market
Lupin’s management refer to multiple indicators suggesting the US generics segment is stabilizing. But traction for some key launches, delivering on pipeline promise, including in the inhalation space, and resolution of compliance issues could hold the key to lifting investor sentiment.
Lupin Q4 Fails To Cheer But Signals Stabilization Of US Generic Market
Lupin’s management refer to multiple indicators suggesting the US generics segment is stabilizing. But traction for some key launches, delivering on pipeline promise, including in the inhalation space, and resolution of compliance issues could hold the key to lifting investor sentiment.